Focused On-demand Library for 5'-nucleotidase domain-containing protein 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q86YG4

UPID:

NT5D4_HUMAN

Alternative names:

Alternative UPACC:

Q86YG4

Background:

The 5'-nucleotidase domain-containing protein 4, identified by its unique accession number Q86YG4, plays a crucial role in nucleotide metabolism. This protein is involved in the hydrolysis of nucleotides to nucleosides, a fundamental process in the cellular energy transfer and signaling pathways. Its specific functions and interactions within the cell offer a rich field for exploration, given its potential involvement in key biological processes.

Therapeutic significance:

Understanding the role of 5'-nucleotidase domain-containing protein 4 could open doors to potential therapeutic strategies. While direct associations with diseases are yet to be established, the protein's fundamental role in nucleotide metabolism suggests its potential impact on conditions related to energy transfer and cellular signaling. Investigating this protein could lead to novel insights into metabolic disorders and pave the way for innovative treatments.